Premium
Are the S panish baseline series markers sufficient to detect contact allergy to corticosteroids in S pain? A GEIDAC prospective study
Author(s) -
MercaderGarcía Pedro,
PastorNieto María A.,
GarcíaDoval Ignacio,
GiménezArnau Ana,
GonzálezPérez Ricardo,
FernándezRedondo Virginia,
SerraBaldrich Ester,
CordobaGuijarro Susana,
GaticaOrtega María E.,
SilvestreSalvador Juan F.
Publication year - 2018
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/cod.12874
Subject(s) - medicine , corticosteroid , budesonide , allergy , betamethasone , mometasone furoate , dermatology , methylprednisolone , methylprednisolone acetate , contact dermatitis , fluticasone propionate , immunology
Summary Background Corticosteroids are among the most commonly used topical drugs. C ontact allergy to these exists, but can be easily missed. Corticosteroid screening markers have been included in the baseline series with the aim of detecting most of the sensitized patients. Objectives To assess the prevalence of contact allergy to topical corticosteroids in S pain and examine the usefulness of corticosteroid markers to detect contact allergy to corticosteroids. Methods In total, 3699 patients referred to 20 dermatology departments across S pain for patch testing with the baseline series, including budesonide and tixocortol pivalate, were also tested with six supplementary corticosteroids (methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17‐valerate, and betamethasone 17,21‐dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17‐butyrate. Results Fifty‐four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty‐nine (1.05%) reacted to at least one of the additionally tested corticosteroids; among these, 24 of 39 (61.5%) did not react to any of the corticosteroid allergy screening markers tested. Conclusions More than half of the patients who were allergic to the additionally tested corticosteroids were not detected with the corticosteroid allergy markers. An update of the corticosteroid allergy screening markers is encouraged, with consideration of group 3 corticosteroids.